# C16008 (NCT01383928)

> Study of Oral IXAZOMIB in Combination With Lenalidomide and Dexamethasone in Participants With Newly Diagnosed Multiple Myeloma

No report yet. It can be ordered.

- Drugs tested: ixazomib plus lenalidomide plus dexamethasone
- Indication: newly diagnosed multiple myeloma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01383928
- Phase: PHASE1, PHASE2
- Status: COMPLETED
- Sponsor: Millennium Pharmaceuticals, Inc.
- Conditions: Multiple Myeloma
- Interventions: Ixazomib; Lenalidomide; Dexamethasone
- Enrollment: 64
- Primary outcome: Phase 1: Maximum Tolerated Dose (MTD)
- Primary outcome: Phase 1: Recommended Phase 2 Dose (RP2D)
- Primary outcome: Phase 1: Percentage of Participants Experiencing 1 or More Treatment-Emergent Adverse Events (TEAEs) or Serious Adverse Events (SAEs)
- Primary outcome: Phase 1: Number of Participants With Markedly Abnormal Laboratory Values Reported as Treatment Emergent Adverse Events (TEAEs)
- Primary outcome: Phase 1: Number of Participants With Treatment-Emergent Adverse Events (TEAE) Related to Neurotoxicity
- Primary outcome: Phase 1: Number of Participants With Clinically Significant Change From Baseline in Vital Signs
- Primary outcome: Phase 2: Percentage of Participants With Complete Response (CR) + Very Good Partial Response (VGPR)
- Primary outcome: Phase 2: Percentage of Participants With Grade 3 or Higher Adverse Events
- Primary outcome: Phase 2: Percentage of Participants Experiencing Serious Adverse Events
- Primary outcome: Phase 2: Percentage of Participants With Treatment-Emergent Adverse Events Resulting in Study Drug Discontinuation

## Indexed commentary on C16008 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 YouTube videos
- 1 post on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=c16008-nct01383928